2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1890
    CEF14, EBV Rta Protein (28-37) 216862-58-7 98%
    CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).
    CEF14, EBV Rta Protein (28-37)
  • HY-P1892
    Competence-Stimulating Peptide-12261 1235882-91-3 98%
    Competence-Stimulating Peptide-12261, a sixteen peptide, is a fragment of competence-stimulating peptide. Competence-Stimulating Peptide, a quorum-sensing molecule, competence-stimulating peptide (CSP) which inhibits germ tube (GT) formation.
    Competence-Stimulating Peptide-12261
  • HY-P1911
    CEF27, Epstein-Barr Virus BRLF-1 lytic (148-156) 254110-79-7 98%
    CEF27, Epstein-Barr Virus BRLF-1 lytic 148-156 corresponding to amino acids 148-156 of the BRLF1 protein. BRLF1 is a transcriptional activator that binds directly to a GC-rich motif present in some Epstein-Barr virus (EBV) lytic gene promoters.
    CEF27, Epstein-Barr Virus BRLF-1 lytic (148-156)
  • HY-P1916
    FliC, Serotype a (427-441), S.paratyphi A 857678-38-7 98%
    FliC, Serotype a (427-441), S.paratyphi A is amino acids 427 to 441 fragment belongs to the FliC, serotype a of the S. FliC epitope.
    FliC, Serotype a (427-441), S.paratyphi A
  • HY-P1974
    FR 901379 144371-88-0 98%
    FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635).
    FR 901379
  • HY-P1978
    CysHHC10 1408311-03-4 98%
    CysHHC10 is a synthetic antimicrobial peptide (AMP), and exhibits strong anti-microbial properties against both Gram-positive and Gram-negative bacteria. The MIC values of CysHHC10 against E. coli, P. aeruginosa, S. aureus and S. epidermidis are 10.1 mM, 20.2 mM, 2.5 mM and 1.3 mM, respectively.
    CysHHC10
  • HY-P2011
    Cephabacin M4 99313-74-3 98%
    Cephabacin M4 is a cephalosporin component, a 7-methoxydesacetylcephalosporin. Cephabacin M4 can be isolated from the culture filtrate of Xanthomonas lactamica.
    Cephabacin M4
  • HY-P2015
    Diacetylsplenopentine 91418-71-2 98%
    Diacetylsplenopentine (BCH 069) is an antiviral agent, and protects guinea pigs from foot-and-mouth disease (FMD) infection. Berlopentin has immunostimulatory properties.
    Diacetylsplenopentine
  • HY-P2020
    Berninamycin A 58798-97-3 98%
    Berninamycin A is a cyclic thiopeptide antibiotic first isolated from S. bernensis. It inhibits protein biosynthesis in Gram positive bacteria through binding with ribosomal subunits. Cyclic thiopeptide antibiotics, including berninamycin A, induce the transcriptional activator TipA in Streptomyces.
    Berninamycin A
  • HY-P2038
    Cephabacin M6 99313-73-2 98%
    Cephabacin M6 is a cephalosporin component, a 7-methoxydesacetylcephalosporin. Cephabacin M6 can be isolated from the culture filtrate of Xanthomonas lactamica.
    Cephabacin M6
  • HY-P2047
    Lavendomycin 82987-09-5 98%
    Lavendomycin is a peptide antibiotic from Streptomyces. Lavendomycin inhibits Gram-positive bacteria.
    Lavendomycin
  • HY-P2054
    Mvt-101 125552-93-4 98%
    Mvt-101 is a hexapeptide-based inhibitor of HIV-1 protease. Mvt-101 is also reduced-peptide-bond inhibitor. Mvt-101 inhibits reproduction of the HIV virus by blocking protease action.
    Mvt-101
  • HY-P2064
    Lariatin A 732286-09-8 98%
    Lariatins is a novel anti-mycobacterial peptides with a lasso structure produced by Rhodococcus jostii K01-B0171.
    Lariatin A
  • HY-P2070
    Aspartocin D 1211953-97-7 98%
    Aspartocin D is an analogue of Amphomycin (HY-P3078). Aspartocin D shows antimicrobial activities against Gram-positive bacteria.
    Aspartocin D
  • HY-P2073
    Cyclo(δ-Ala-L-Val) 25516-00-1 98%
    Cyclo(Δ-Ala-L-Val) is a cyclic dipeptide and a putative quinolone signal (QS) molecule produced by Pseudomonas aeruginosa.
    Cyclo(δ-Ala-L-Val)
  • HY-P2087
    Bassianolide 64763-82-2 98%
    Bassianolide is a cyclooligomer depsipeptide secondary metabolite. Bassianolide is an insecticidal virulence factor of Beauveria bassiana. Bassianolide inhibits acetylcholine-induced smooth muscle contraction, and shows moderate antiplasmodial and anti-mycobacterial activities.
    Bassianolide
  • HY-P2098
    Alamethicin F 50 56165-93-6 98%
    Alamethicin F 50 is an antibiotic. Alamethicin F 50 is composed of membrane-active peptide, containing 75% Alamethicin F 50/5 and 10% Alamethicin F 50/7. Alamethicin F 50 is exhibits antifungal and antibacterial activity by disrupting the integrity of microbial cell membranes, resulting in leakage of cell contents and death of the microorganisms. Alamethicin F 50 is able to reduce the surface tension of water, which can be used as a surfactant or detergent.
    Alamethicin F 50
  • HY-P2170
    XMP-629 316805-65-9 98%
    XMP-629 (XOMA-629), a cationic α-helical peptide, is a potent endotoxin inhibitor. XMP-629 exhibits broad-spectrum antimicrobial activity via an immunomodulatory mechanism. XOMA 629 has antimicrobial activity against Propionibacterium acnes, Staphylococcus aureus and Streptococcus pyogenesand.
    XMP-629
  • HY-P2200
    Siamycin I 164802-68-0 98%
    Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research.
    Siamycin I
  • HY-P2206
    Zelkovamycin 221197-33-7 98%
    Zelkovamycin is a cyclic peptide antibiotic originally isolated from Streptomyces. It inhibits growth of X. oryzae, P. oryzae, S. aureus, and A. laidlawii in a concentration-dependent manner when used at concentrations ranging from 0.01 to 300 μg/mL.
    Zelkovamycin
Cat. No. Product Name / Synonyms Application Reactivity